EP0752879A4 - TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES - Google Patents

TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES

Info

Publication number
EP0752879A4
EP0752879A4 EP95915653A EP95915653A EP0752879A4 EP 0752879 A4 EP0752879 A4 EP 0752879A4 EP 95915653 A EP95915653 A EP 95915653A EP 95915653 A EP95915653 A EP 95915653A EP 0752879 A4 EP0752879 A4 EP 0752879A4
Authority
EP
European Patent Office
Prior art keywords
treatment
autoimmune disease
oral tolerization
enhancing cytokines
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95915653A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0752879A1 (en
Inventor
Howard L Weiner
Youhai Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP0752879A1 publication Critical patent/EP0752879A1/en
Publication of EP0752879A4 publication Critical patent/EP0752879A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95915653A 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES Withdrawn EP0752879A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225372 1994-04-08
US33252494A 1994-10-31 1994-10-31
US332524 1994-10-31
PCT/US1995/004512 WO1995027500A1 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES

Publications (2)

Publication Number Publication Date
EP0752879A1 EP0752879A1 (en) 1997-01-15
EP0752879A4 true EP0752879A4 (en) 1999-07-21

Family

ID=26919544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95915653A Withdrawn EP0752879A4 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASES WITH TOLERANCE INDUCING AGENTS AND / OR ORAL TH2-ENHANCING CYTOKINES

Country Status (10)

Country Link
EP (1) EP0752879A4 (no)
JP (1) JPH09511990A (no)
KR (1) KR970702067A (no)
AU (1) AU695883B2 (no)
BR (1) BR9507452A (no)
CA (1) CA2187345A1 (no)
HU (1) HUT76101A (no)
IL (1) IL113301A0 (no)
NO (1) NO964200L (no)
WO (1) WO1995027500A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
CA2263730A1 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL126714A (en) * 1997-02-28 2010-12-30 Enzo Therapeutics Inc Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
CA2410563C (en) 2000-05-24 2013-04-23 John M. Hallenbeck Methods for preventing strokes by inducing tolerance to e-selectin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011030A1 (en) * 1990-12-19 1992-07-09 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
EP0603992A1 (en) * 1992-12-22 1994-06-29 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190750A (en) * 1990-03-09 1993-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011030A1 (en) * 1990-12-19 1992-07-09 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1993016724A1 (en) * 1992-02-28 1993-09-02 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
EP0603992A1 (en) * 1992-12-22 1994-06-29 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9527500A1 *

Also Published As

Publication number Publication date
NO964200D0 (no) 1996-10-03
NO964200L (no) 1996-10-03
AU695883B2 (en) 1998-08-27
BR9507452A (pt) 1997-08-05
KR970702067A (ko) 1997-05-13
HUT76101A (en) 1997-06-30
EP0752879A1 (en) 1997-01-15
JPH09511990A (ja) 1997-12-02
AU2246795A (en) 1995-10-30
CA2187345A1 (en) 1995-10-19
HU9602751D0 (en) 1996-11-28
IL113301A0 (en) 1995-07-31
WO1995027500A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
HK1095265A1 (en) Prevention and treatment of amyloidogenic disease
SG49658A1 (en) Treatment of condition and disease
ZA9710339B (en) Xanthines and their therapeutic use
SG43798A1 (en) Agonists and antagonistis of human interleukin-10
HU9602751D0 (en) Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
IL113303A0 (en) Treatment of autoimmune disease using oral tolerization and/or type I interferon
EP1030663A4 (en) TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
AU7257696A (en) Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
HUP9900147A3 (en) Therapeutic agents and autoimmune diseases
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
GB9419571D0 (en) Treatment of oral infections
PL322002A1 (en) Variants of human dnase i
IL112681A0 (en) Opioid peptides for the treatment of pain and use thereof
EP0833641A4 (en) TREATMENT AND PREVENTION OF PROSTATE DISEASES
GB9611500D0 (en) Prevention and treatment of oral conditions with peptides having anti-adherence activity
IL115017A0 (en) Methods of maintaining teeth and oral bone
IL124576A0 (en) Compositions and methods for the prevention and treatment of oral mucositis
GB9516572D0 (en) Prevention and/or treatment of disease
HU9400634D0 (en) Vaccine and diagnosticum against parvovirosis of gooses and barbari duks
EG20171A (en) Treatment of conditions and disease
ZA97210B (en) Oral administration of effective amunts of forms of hyaluronic acid
ZA951440B (en) Novel opiold peptides for the treatment of pain and use thereof
BG99596A (en) Preparation for the treatment of gums and teeth
HU9400486D0 (en) International encyclopaedia on research and therapy of medicine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990608

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000529